In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mast Therapeutics, Inc.

https://savarapharma.com/

Latest From Mast Therapeutics, Inc.

Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs

Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.

United Kingdom Health Technology Assessment

Roche's SERD Setback Means Menarini Retains An Edge

Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.

Cancer Clinical Trials

Sanofi's SERD Candidate Founders In Advanced Breast Cancer

The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.

Cancer Clinical Trials

Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook

Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.

Deals Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Other Names / Subsidiaries
    • Adventrx Pharmaceuticals, Inc.
    • Aires Pharmaceuticals, Inc.
    • SynthRx, Inc.
UsernamePublicRestriction

Register